SCYNEXIS, Inc. (NASDAQ:SCYX) insider Gonzalez David Angulo bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was purchased at an average cost of $1.55 per share, with a total value of $15,500.00. Following the completion of the transaction, the insider now owns 72,000 shares in the company, valued at $111,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

SCYNEXIS, Inc. (NASDAQ SCYX) traded up 6.41% during mid-day trading on Monday, reaching $1.66. The company’s stock had a trading volume of 133,136 shares. The firm’s market capitalization is $42.82 million. The stock’s 50-day moving average is $1.77 and its 200-day moving average is $2.33. SCYNEXIS, Inc. has a 12 month low of $1.52 and a 12 month high of $5.51.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: SCYNEXIS, Inc. (SCYX) Insider Buys 10,000 Shares of Stock” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/insider-buying-scynexis-inc-scyx-insider-buys-10000-shares-of-stock/1488182.html.

A number of analysts recently issued reports on SCYX shares. Needham & Company LLC cut SCYNEXIS from a “buy” rating to a “hold” rating in a research report on Tuesday, May 9th. Aegis reissued a “buy” rating on shares of SCYNEXIS in a research report on Tuesday, May 30th. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. ValuEngine raised SCYNEXIS from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Finally, Roth Capital started coverage on SCYNEXIS in a research report on Monday, July 10th. They issued a “buy” rating and a $8.50 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $10.22.

A number of institutional investors have recently bought and sold shares of the company. DAFNA Capital Management LLC increased its position in SCYNEXIS by 32.7% in the second quarter. DAFNA Capital Management LLC now owns 506,900 shares of the company’s stock worth $907,000 after buying an additional 125,000 shares during the period. Vanguard Group Inc. increased its position in SCYNEXIS by 6.0% in the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock worth $1,554,000 after buying an additional 48,978 shares during the period. GSA Capital Partners LLP increased its position in SCYNEXIS by 33.7% in the second quarter. GSA Capital Partners LLP now owns 176,700 shares of the company’s stock worth $316,000 after buying an additional 44,500 shares during the period. Federated Investors Inc. PA increased its position in SCYNEXIS by 23.5% in the second quarter. Federated Investors Inc. PA now owns 4,208,400 shares of the company’s stock worth $7,533,000 after buying an additional 800,040 shares during the period. Finally, Iguana Healthcare Management LLC increased its position in SCYNEXIS by 20.0% in the first quarter. Iguana Healthcare Management LLC now owns 300,000 shares of the company’s stock worth $828,000 after buying an additional 50,000 shares during the period. Institutional investors and hedge funds own 48.53% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.